EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

1

EULAR updated its Behçet’s syndrome management recommendations, emphasizing earlier biologic use for severe organ involvement.
2

Colchicine remains the first-line treatment for mucocutaneous involvement, with alternatives like apremilast for refractory cases.
3

For Behçet’s uveitis, immunosuppressive treatment is essential, with infliximab preferred for sight-threatening inflammation.
4

The task force recommends high-dose glucocorticoids plus infliximab for arterial involvement, reflecting new evidence supporting this approach.
5

The recommendations highlight the need for individualized treatment and multidisciplinary care to maximize patient quality of life.

1